Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"PAOPA"”.
-
Characterizing the cognitive, behavioural, and mechanistic actions of novel allosteric modulator PAOPA for the treatment of schizophrenia
… thesis aimed to evaluate a new drug candidate. PAOPA is a novel allosteric modulator that increases dopamine binding to the dopamine D2 receptor. It has previously shown positive findings in preventing and reversing behaviours proposed to model phenotypes of schizophrenia. However, it has not …
-
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioural and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
… at the dopamine D2 receptor. Of these compounds, PAOPA is the most potent allosteric modulator, and has been shown to be effective in treating the MK-801 induced preclinical animal model of schizophrenia without causing the adverse effects induced by currently prescribed antipsychotic drugs. The …
-
Characterization of the Mechanism of Action for Novel Dopamine D2 Receptor Allosteric Modulators
… inylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) (PCT/CA2011/000968), have shown robust preclinical efficacy in treating models of Parkinson’s disease, depression, tardive dyskinesia and schizophrenia. These ligands modulate agonist binding to the D2 receptor in a biphasic manner, although …
-
The Investigation and Development of Novel Molecules, Models and Tools for the Treatment and Study of Schizophrenia
… regulate binding without blocking the receptor. PAOPA, a dopamine D2 receptor allosteric modulator, prevents and treats schizophrenia-like symptoms in pre-clinical animal models of schizophrenia with no apparent adverse effects. The studies outlined in this thesis further categorize PAOPA as a …
-
Novel Antipsychotic Drug Carriers: The Development of Nanoparticle and Microgel Drug Carriers for Antipsychotic Delivery in the Treatment of Schizophrenia
… inylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) and poly(ethylene glycol)–block-poly(D,L-lactic-co-glycolic acid) (PEG-PLGA) nanoparticles loaded with haloperidol were prepared with narrow size distributions and sizes < 135 nm. The microgels and nanoparticles exhibited high <em>Solanum …
-
Hydrogel-Based Intranasal Drug Delivery Platforms
… controlled release of anti-psychotic drug (PAOPA) in an MK-801 pre-clinical model of schizophrenia. Results indicate that PAOPA-loaded SNP-CMC in-situ gelled hydrogels provide a sustained released profile such that they alleviate negative symptoms associated with schizophrenia (decreased …
-
Design & Fabrication of Nanostructured Hydrogels From Biopolymer Nanoparticle Building Blocks for Biomedical and Environmental Applications
… controlled release of the peptide drug PAOPA, a positive allosteric modulator of dopamine D2 receptor. Selected gels shown to alleviate negative behavioural abnormalities associated with for up to 72 hours in pre-clinical rat models of schizophrenia at a low drug dosage (0.5 mg/kg), …